Effects of small interfering RNAs targeting MAPK1 on gene expression profile in HeLa cells as revealed by microarray analysis

Cell Biology International

Volumn 32, Issue 9, 2008, Pages 1081-1090

  Huang, Chen ^a   Liu, Li Ying ^a   Li, Zong Fang ^a   Wang, Pei ^a   Ni, Lei ^a   Song, Li Ping ^a   Xu, De Hui ^a   Song, Tu Sheng ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Apoptosis; HeLa cell; MAPK 1; Microarray; siRNA

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; CYCLIN DEPENDENT KINASE; GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; NUCLEOPORIN; NUCLEOPORIN 188; PROTEIN; SMALL INTERFERING RNA; SMALL INTERFERING RNA 2; STAT1 PROTEIN; STAT2 PROTEIN; SYNAPTOPHYSIN;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL GROWTH; CONTROLLED STUDY; CYTOSKELETON; DOWN REGULATION; GENE EXPRESSION PROFILING; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN FAMILY; REAL TIME POLYMERASE CHAIN REACTION; UNINDEXED SEQUENCE; UPREGULATION;

APOPTOSIS; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HELA CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 49949116885     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2008.04.019     Document Type: Article

References (40)

1. Ahn N.G., Seger R., Bratlien R.L., Diltz C.D., Tonks N.K., and Krebs E.G. Multiple components in an epidermal growth factor-stimulated protein kinase cascade. In vitro activation of a myelin basic protein/microtubule-associated protein-kinase. J Biol Chem 266 7 (1991) 4220-4227
2. Apple S.K., Hecht J.R., Lewin D.N., Jahromi S.A., Grody W.W., and Nieberg R.K. Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis. Hum Pathol 30 2 (1999) 123-129
3. Boulton T.G., Nye S.H., Robbins D.J., Ip N.Y., Radziejew ska E., Morgenbesser S.D., et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65 4 (1991) 663-675
4. Bridge A.J., Pebernard S., Ducraux A., Nicoulaz A.L., and Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34 3 (2003) 263-264
5. Chen L., He H.Y., Li H.M., Zheng J., Heng W.J., You J.F., et al. ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett 215 2 (2004) 239-247
6. Chen T.P., Chen C.M., Chang H.W., Wang J.S., Chang W.C., Hsu S.I., et al. Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms. Gynecol Oncol 104 3 (2007) 516-523
7. Crooke S.T. Antisense strategies. Curr Mol Med 4 5 (2004) 465-487
8. D'Amico T.A., and Harpole Jr. D.H. Molecular biology of esophageal cancer. Chest Surg Clin N Am 10 3 (2000) 451-469
9. deFazio A., Chiew Y.E., Sini R.L., Janes P.W., and Sutherland R.L. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. Int J Cancer 87 4 (2000) 487-498
10. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76 6 (1994) 1025-1037
11. Douziech N., Calvo E., Laine J., and Morisset J. Activation of MAP kinases in growth responsive pancreatic cancer cells. Cell Signal 11 8 (1999) 591-602
12. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics, 2001. CA Cancer J Clin 51 1 (2001) 15-36
13. Han J., Lee J.D., Bibbs L., and Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265 5173 (1994) 808-811
14. Heidel J.D., Hu S., Liu X.F., Triche T.J., and Davis M.E. Lack of interferon response in animals to naked SiRNAs, Nat Biotechnol 22 12 (2004) 1579-1582
15. Hellstrom I., Goodman G., Pullman J., Yang Y., and Hellstrom K.E. Overexpression of HER-2 in ovarian carcinomas. Cancer Res 61 6 (2001) 2420-2423
16. Hiraoka S., Kato J., Tatsukawa M., Harada K., Fujita H., Morikawa T., et al. Laterally spreading type of colorectal adenoma exhibits a unique methylation phenotype and K-ras mutations. Gastroenterology 131 2 (2006) 379-389
17. Huang C., Liu L.Y., Song T.S., Ni L., Song L.P., and Si L.S. Inhibition of the expression of p42 MAPK in HeLa cell line by RNA interference. Zhonghua Bing Li Xue Za Zhi 35 5 (2006) 292-295
18. Imaizumi M., Nishimura M., Takeuchi S., Murase M., and Hamaguchi M. Role of tyrosine specific phosphorylation of cellular proteins, especially EGF receptor and p125FAK in human lung cancer cells. Lung Cancer 17 1 (1997) 69-84
19. Jin K., Mao X.O., Zhu Y., and Greenberg D.A. MEK and ERK protect hypoxic cortical neurons via phosphorylation of Bad. J Neurochem 80 1 (2002) 119-125
20. Kariko K., Bhuyan P., Capodici J., Ni H., Lubinski J., Friedman H., et al. Exogenous SiRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. Cells Tissues Organs 177 3 (2004) 132-138
21. Kyriakis J.M., and Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81 2 (2001) 807-869
22. Lee H.J., Bach J.H., Chae H.S., Lee S.H., Joo W.S., Choi S.H., et al. Mitogen-activated protein kinase/extracellular signal-regulated kinase attenuates 3-hydroxykynurenine-induced neuronal cell death. J Neurochem 88 3 (2004) 647-656
23. Lee do Y., Lee M.W., Lee H.J., Noh Y.H., Park S.C., Lee M.Y., et al. ERK1/2 activation attenuates TRAIL-induced apoptosis through the regulation of mitochondria-dependent pathway. Toxicol In Vitro 20 6 (2006) 816-823
24. Mayr D., Hirschmann A., Lohrs U., and Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 103 3 (2006) 883-887
25. Payne D.M., Rossomando A.J., Martino P., Erickson A.K., Her J.H., Shabanowitz J., et al. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J 10 4 (1991) 885-892
26. Rice P.L., Beard K.S., Driggers L.J., and Ahnen D.J. Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites. Cancer Res 64 22 (2004) 8148-8151
27. Robbins D.J., Zeng E., Owaki H., Vanderbilt C.A., Ebert D., Geppert T.D., et al. Regulation and properties of extracellular signal-regulated protein kinases 1 and 2 in vitro. J Biol Chem 268 7 (1993) 5097-5106
28. Rolitsky C.D., Theil K.S., McGaughy V.R., Copeland L.J., and Niemann T.H. HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 18 2 (1999) 138-143
29. Schmidt C.M., Wang Y., Wiesenauer C., Yip-Schneider M., and Wu M. Novel combination of a COX-2 inhibitor, NS398, and MEK inhibitor, U0126, in human hepatocellular carcinoma provides synergistic increase in apoptosis. J Gastrointest Surg 7 8 (2003) 1024-1033
30. Scoccia B., Lee Y.M., Niederberger C., and Ilekis J.V. Expression of the ErbB family of receptors in ovarian cancer. J Soc Gynecol Investig 5 3 (1998) 161-165
31. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4 12 (2004) 937-947
32. Seger R., and Krebs E.G. The MAPK signaling cascade. FASEB J 9 9 (1995) 726-735
33. Simon C., Hicks M.J., Nemechek A.J., Mehta R., O'Malley Jr. B.W., Goepfert H., et al. PD098059, an inhibitor of ERK1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma. Br J Cancer 80 9 (1999) 1412-1419
34. Sledz C.A., Holko M., de Veer M.J., Silverman R.H., and Williams B.R. Activation of the interferon system by short-interfering RNAs, Nat Cell Biol 5 9 (2003) 834-839
35. Specht M.C., Barden C.B., and Fahey T.J. p44/p42-MAP kinase expression in papillary thyroid carcinomas. Surgery 130 6 (2001) 936-940
36. Steinmetz R., Wagoner H.A., Zeng P., Hammond J.R., Hannon T.S., Meyers J.L., et al. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol Endocrinol 18 10 (2004) 2570-2582
37. Tuziak T., Olszewski W.P., Olszewski W., and Pienkowski T. Expression of HER2/neu in primary and metastatic breast cancer. Pol J Pathol 52 1-2 (2001) 21-26
38. van der Valk P., Lindeman J., and Kamphorst W. Growth factor profiles of human gliomas. Do non-tumour cells contribute to tumour growth in glioma. Ann Oncol 8 10 (1997) 1023-1029
39. Winkler K.E. Killing the messenger. Nat Rev Drug Discov 3 10 (2004) 823-824
40. Yung H.W., Wyttenbach A., and Tolkovsky A.M. Aggravation of necrotic death of glucose-deprived cells by the MEK1 inhibitors U0126 and PD184161 through depletion of ATP. Biochem Pharmacol 68 2 (2004) 351-360